Why is the cheese sandwich the downfall of AI carb counting, even with “3D scanning”?
A slightly rhetorical question, I’ll admit, but a pertinent one. Once again, I have been trying out the latest (read most heavily pushed on Facebook […]
Diabetes
The Libre Duo. A platform prototype to move care from the hospital to the home?
Abbott has put glucose and ketones on the same wearable, and the launch coverage is all about DKA. Worth having if you’re on a pump, which is fine as far as it goes, but it misses the bit that makes this interesting. Because if you look at what Abbott has actually built across its other divisions, and what they’ve patented alongside it, the Libre Duo doesn’t really look like a ketone sensor. It looks like the platform prototype and the first visible piece of an infrastructure designed to move chronic disease care out of outpatients and into the home. And the policy environment for that shift has just been locked in on both sides of the Atlantic for the next five years.
Five AI models, three users, one finding: the settings came from the textbook, not the data
We took Nightscout data from three people and gave it to 5 Large Language Models with a detailed prompt to see how they would respond.
The results weren’t what I was expecting.
I Asked AI to Count My Carbs 27,000 Times. It Couldn’t Give Me the Same Answer Twice.
Ask ChatGPT to estimate the carbs in your lunch. Now ask it again. And again. Five hundred times. You’d expect the same answer each time. […]
100% Insulin Independence: Why Eledon’s Breakthrough is a Pillar, Not a Cure
Eledon Pharmaceuticals recently achieved 100% insulin independence in an early-phase islet transplant trial using its anti-CD40L drug, tegoprubart. It’s a massive step forward in transplant immunology that avoids the toxicity of standard drugs. But why isn’t it a cure yet, and how does it fit into the actual blueprint of a functional cure?
Explore a Decade of Diabetes Insights with Diabettech AI
After 10+ years of documenting the diabetes landscape, Diabettech is launching diabettech.ai—a custom research tool designed to help you navigate a decade’s worth of articles and reports. Powered by an LLM interface, this tool allows you to “interrogate” the site’s data to find specific answers on everything from cures to n=1 observations.
Key highlights of the beta launch:
Targeted Accuracy: Built to stick strictly to Diabettech articles and comments to minimize “hallucinations.”
Research-Focused: Optimized as a precision tool rather than a standard chatbot to provide relevant article links.
Sustainable Design: Privately funded and optimized for efficiency to manage resource costs and query speeds.
Ready to dive into the archives? Visit diabettech.ai to start your research and share your feedback on the beta experience.
Now We Know What a Type 1 Cure Could Look Like
The Type 1 cure is no longer theoretical. Human data now points to a blueprint: working cells, immune evasion, and durable immune modulation.
What If Type 1 Diabetes Was Treatable — If You Found It Early Enough?
For most of its history, type 1 diabetes (T1D) has been diagnosed late. By the time symptoms appear, the autoimmune destruction of pancreatic beta cells […]
A “twiist” of Fate: Why Sequel is Moving Beyond Tidepool to Embrace Diabeloop
For those in the “We Are Not Waiting” camp, the Sequel twiist pump was supposed to be the commercial homecoming for Tidepool Loop. It promised […]
Introducing The Daily Bolus: Parsing the Signal from the Noise
Date: January 13, 2026 If you’ve been following Diabettech for a while, you know that my focus has always been on the deep dives—the “Nine […]